Century Therapeutics, Inc. (NASDAQ:IPSC) Receives Consensus Recommendation of “Buy” from Analysts

Century Therapeutics, Inc. (NASDAQ:IPSCGet Rating) has earned a consensus recommendation of “Buy” from the six ratings firms that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $32.00.

A number of research analysts recently weighed in on IPSC shares. Piper Sandler lowered their target price on shares of Century Therapeutics from $38.00 to $22.00 and set an “overweight” rating on the stock in a research note on Monday. SVB Leerink reiterated a “buy” rating and issued a $32.00 price target on shares of Century Therapeutics in a research note on Friday, March 18th. Zacks Investment Research upgraded shares of Century Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 3rd. Finally, William Blair assumed coverage on shares of Century Therapeutics in a research note on Thursday, May 12th. They issued a “market perform” rating on the stock.

Shares of IPSC traded down $0.39 during trading hours on Thursday, reaching $8.40. 93,567 shares of the stock traded hands, compared to its average volume of 109,383. The company has a current ratio of 14.57, a quick ratio of 14.57 and a debt-to-equity ratio of 0.03. Century Therapeutics has a 52-week low of $7.32 and a 52-week high of $32.90. The company’s 50-day moving average price is $11.43 and its two-hundred day moving average price is $14.10. The company has a market cap of $494.19 million and a P/E ratio of -2.54.

Century Therapeutics (NASDAQ:IPSCGet Rating) last released its earnings results on Monday, May 16th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.22). On average, research analysts forecast that Century Therapeutics will post -2.3 EPS for the current year.

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. increased its holdings in shares of Century Therapeutics by 24.3% in the 1st quarter. BlackRock Inc. now owns 1,028,257 shares of the company’s stock worth $12,946,000 after buying an additional 200,834 shares during the last quarter. Deep Track Capital LP increased its holdings in shares of Century Therapeutics by 270.6% in the 1st quarter. Deep Track Capital LP now owns 926,469 shares of the company’s stock worth $11,664,000 after buying an additional 676,469 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Century Therapeutics by 49.6% in the 1st quarter. Vanguard Group Inc. now owns 819,762 shares of the company’s stock worth $10,320,000 after buying an additional 271,760 shares during the last quarter. Marshall Wace LLP increased its holdings in shares of Century Therapeutics by 528.7% in the 4th quarter. Marshall Wace LLP now owns 701,338 shares of the company’s stock worth $11,123,000 after buying an additional 589,786 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in shares of Century Therapeutics in the 4th quarter worth about $6,515,000. Hedge funds and other institutional investors own 57.50% of the company’s stock.

About Century Therapeutics (Get Rating)

Century Therapeutics, Inc, a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.

Recommended Stories

Analyst Recommendations for Century Therapeutics (NASDAQ:IPSC)

Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.